Renal dysfunction in cirrhosis
暂无分享,去创建一个
[1] Constantine J Karvellas,et al. Acute Kidney Injury in Cirrhosis. , 2015, Critical care clinics.
[2] J. Huggins,et al. Point-of-Care Echocardiography Improves Assessment of Volume Status in Cirrhosis and Hepatorenal Syndrome. , 2015, American Journal of the Medical Sciences.
[3] D. Rockey,et al. Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions. , 2014, Journal of hepatology.
[4] F. Carrilho,et al. Terlipressin versus Norepinephrine in the Treatment of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis , 2014, PloS one.
[5] M. Perazella,et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury , 2014, Hepatology.
[6] Paul L. Martin,et al. Renal dysfunction in end-stage liver disease and post-liver transplant. , 2014, Clinics in liver disease.
[7] F. Wong,et al. Kidney damage biomarkers: Novel tools for the diagnostic assessment of acute kidney injury in cirrhosis , 2014, Hepatology.
[8] D. Rockey. To transfuse or not to transfuse in upper gastrointestinal hemorrhage? That is the question , 2014, Hepatology.
[9] L. Magder,et al. A Pilot Study to Evaluate Renal Hemodynamics in Cirrhosis by Simultaneous Glomerular Filtration Rate, Renal Plasma Flow, Renal Resistive Indices and Biomarkers Measurements , 2014, American Journal of Nephrology.
[10] M. Poca,et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. , 2014, Journal of hepatology.
[11] J. Dumortier,et al. Creatinine‐ versus cystatine C‐based equations in assessing the renal function of candidates for liver transplantation with cirrhosis , 2014, Hepatology.
[12] C. Parikh,et al. Reconsidering a “chopped liver”: The need for improving glomular filtration rate estimation for hepatic transplantation , 2014, Hepatology.
[13] R. Moreau,et al. Glomerular filtration rate equations for liver‐kidney transplantation in patients with cirrhosis: Validation of current recommendations , 2014, Hepatology.
[14] L. Magder,et al. Performance of chronic kidney disease epidemiology collaboration creatinine‐cystatin C equation for estimating kidney function in cirrhosis , 2014, Hepatology.
[15] P. Hayes,et al. Review article: advances in the management of patients with cirrhosis and portal hypertension‐related renal dysfunction , 2014, Alimentary pharmacology & therapeutics.
[16] C. Parikh,et al. Acute kidney injury in patients with cirrhosis: perils and promise. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[17] M. Weir,et al. Current Concepts in the Diagnosis and Classification of Renal Dysfunction in Cirrhosis , 2013, American Journal of Nephrology.
[18] K. Moore. Acute kidney injury in cirrhosis: A changing spectrum , 2013, Hepatology.
[19] Johnny C. Hong,et al. Simultaneous Liver–Kidney Transplantation Summit: Current State and Future Directions , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[20] R. Schrier,et al. Renal failure in cirrhosis: prerenal azotemia, hepatorenal syndrome and acute tubular necrosis. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[21] F. Wong,et al. Acute kidney injury in decompensated cirrhosis , 2012, Gut.
[22] T. Nickolas,et al. Urinary Neutrophil Gelatinase-Associated Lipocalin Predicts Mortality and Identifies Acute Kidney Injury in Cirrhosis , 2012, Digestive Diseases and Sciences.
[23] D. Rockey,et al. Acute Kidney Injury and Chronic Kidney Disease in Hospitalized Patients With Cirrhosis , 2011, Journal of Investigative Medicine.
[24] K. Brown,et al. Paneth cell‐derived interleukin‐17A causes multiorgan dysfunction after hepatic ischemia and reperfusion injury , 2011, Hepatology.
[25] J. Dasta,et al. Terlipressin in Hepatorenal Syndrome , 2011, The Annals of pharmacotherapy.
[26] R. Bellomo,et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis , 2011, Gut.
[27] S. Møller. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. , 2010, Journal of hepatology.
[28] R. Moreau,et al. The evaluation of renal function and disease in patients with cirrhosis. , 2010, Journal of hepatology.
[29] R. Schrier,et al. Renal failure in cirrhosis. , 2009, The New England journal of medicine.
[30] N. Raina,et al. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment , 2009, Gut.
[31] V. D’Agati,et al. Acute kidney injury after hepatic ischemia and reperfusion injury in mice , 2008, Laboratory Investigation.
[32] Vicente Arroyo,et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis , 2007, Postgraduate Medical Journal.
[33] E. Esrailian,et al. Octreotide/Midodrine Therapy Significantly Improves Renal Function and 30-Day Survival in Patients with Type 1 Hepatorenal Syndrome , 2007, Digestive Diseases and Sciences.
[34] W. Jiménez,et al. Circulatory function and hepatorenal syndrome in cirrhosis , 2005, Hepatology.
[35] G. Filler,et al. Cystatin C as a marker of GFR--history, indications, and future research. , 2005, Clinical biochemistry.
[36] F. Wong,et al. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome , 2004, Hepatology.
[37] S. Nielsen,et al. Increased urinary excretion of aquaporin 2 in patients with liver cirrhosis , 2003, Gut.
[38] D. Fish,et al. Assessing renal function in cirrhotic patients: problems and pitfalls. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[39] V. Arroyo,et al. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. , 2003, Journal of hepatology.
[40] F. Roudot-thoraval,et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study , 2002, Hepatology.
[41] H. Schild,et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study , 2000, Gut.
[42] T. Risler,et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis mars: Results of a prospective, randomized, controlled clinical trial , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[43] P. Angeli,et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide , 1999, Hepatology.
[44] Rosa Gilabert,et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems , 1998, Hepatology.
[45] J. Schölmerich,et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis , 1996, Hepatology.
[46] D. Schuppan,et al. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. , 1995, Renal failure.
[47] P. Angeli,et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. , 1994, Archives of internal medicine.
[48] I. Osberg,et al. Bilirubin interference with the kinetic Jaffé method for serum creatinine. , 1978, Clinical chemistry.
[49] E. Haber,et al. Characterization of the renin-aldosterone system in decompensated cirrhosis. , 1977, Circulation research.